Good day, and thank you for standing by. Welcome to the AMN Healthcare First Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Randle Reece, Vice President of Investor Relations.

Good afternoon, everyone. Welcome to AMN Healthcare's first quarter 2025 earnings call. A replay of this webcast will be available at ir.amnhealthcare.com at the conclusion of this call. Remarks we make during this call about future expectations, projections, trends, plans, events or circumstances constitute forward-looking statements. These statements reflect the company's current beliefs based upon information currently available to it. Our actual results may differ materially from those indicated by these forward-looking statements because of various factors and cautionary statements, including those identified in our most recently filed forms 10-K and 10-Q, our earnings release and subsequent filings with the SEC. Company does not intend to update guidance or any forward-looking statements provided today prior to its next earnings release. This call contains certain non-GAAP financial information. Information regarding and reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in our earnings release and on our financial reports page at ir.amnhealthcare.com. On the call with me today are Cary Grace, President and Chief Executive Officer; and Brian Scott, Chief Financial and Operating Officer. I will now turn the call over to Cary.

Thank you, Randy, and welcome to our first quarter conference call. The AMN team showed off its energy and resource units in the first quarter and the results for revenue and profit margins that exceeded the high end of guidance. Revenue of $690 million topped the high end of guidance by $10 million due to strength in our labor disruption, Locum Tenens and Allied businesses. Our other businesses on balance were in line with our revenue forecast. The company reported $64 million in adjusted EBITDA and another quarter of robust cash flow and debt reduction. Thank you to our healthcare professionals and the entire AMN team for delivering a solid start to the year. For the second quarter, our outlook for revenue and earnings compares well against consensus estimates with continued upside from labor disruption locum tenens and Allied staffing revenue. We received $39 million in revenue from two labor disruption events in the first quarter with continued activity in the second quarter. Increasingly, labor disruption has become a differentiated solution that supports an important client needs. We have built the leading event management technology and strengthened our ability to manage labor disruption activities without interrupting the strong service quality in our core business. These differentiating capabilities have been greeted by a series of client wins and a large pipeline of opportunities, which could offer upside potential this year and next. Bookings for locum tenens picked up significantly in the first four months of the year. We expect locum tenens to have sequential revenue growth this quarter, with good momentum going into the rest of the year. Demand for our Allied business has grown mid-teens year-over-year. We continue to see healthy Allied demand into this quarter and strong execution from our team. In our schools business, bookings for the next…

Thank you, Cary, and good afternoon, everyone. First quarter consolidated revenue was $690 million, above the high end of guidance driven primarily from better-than-expected performance in labor disruption, locum and Allied. Revenue was down 16% from the prior year and down 6% sequentially. Consolidated gross margin for the first quarter was 28.7%, 10 basis points above the high end of our guidance range. Year-over-year, gross margin decreased 270 basis points while sequentially, gross margin was down 110 basis points. Consolidated SG&A expenses were $148 million compared with $175 million in the prior year and $159 million in the previous quarter. Adjusted SG&A, which excludes certain expenses, was $136 million in the first quarter or 19.7% of revenue compared with $162 million or 19.7% of revenue in the prior year and $145 million or 19.8% of revenue in the previous quarter. The year-over-year SG&A decline was primarily due to lower employee headcount and variable compensation along with reduced consulting and bad debt expenses. The sequential decrease was mainly a result of lower compensation expense and favorable bonus and related accrual adjustments. First quarter Nurse and Allied revenue was $413 million, down 20% from the prior year primarily from lower volume and rates, partially offset by increased labor disruption revenue. Sequentially, segment revenue was down 9%, mainly driven by lower labor disruption revenue, a modest volume decline in two fewer days. Year-over-year, segment volume decreased 22%. Average rate was down 5% and average hours worked was down 1%. Sequentially, volume was down 2%, and the average rate and hours worked were both 1% higher. Travelers revenue in the first quarter was $215 million, a decrease of 36% from the prior year period and 6% from the prior quarter. Allied revenue in the quarter was $147 million, down 13% year-over-year and 1% sequentially.…

Thank you, Brian. This week is National Nurses Week and May is National Nurses Month. The theme of nurses week this year is the Power of Nurses, and we are extremely grateful for the profound difference that nurses make in the health of all Americans. I encourage everyone to share our appreciation for nurses everywhere, including the thousands of nurses who are part of the AMN family. Our 2025 RN survey showed that 8 in 10 nurses want to see improvement at their workplace in three areas: patients to nurse ratio, flexible scheduling and administrative burdens. We at AMN are continually working on innovative and flexible talent solutions to support nurses physical and mental well-being and improvement of work life balance to combat burnout. Our business depends on the quality of people we bring to serve the steadily growing demand of providing healthcare. So far in 2025, we have been thrilled to welcome top talent from across the industry on to the AMN team. These superb professionals have joined us in client-facing and key leadership positions. Our dedication to quality and innovation is making AMN a prime destination for the best people in the business. In further demonstration of our dedication to the highest quality, AMN again has received certification from the Joint Commission on the Accreditation of Healthcare Organizations. AMN was the first healthcare staffing company to receive this certification, and we have continuously maintained it since 2005. Before we move to questions, I want to take a moment to acknowledge the recent passing of Healthcare's founder and long-time CEO, Alan Brenan. On behalf of AMN Healthcare, we extend our deepest condolences to Allan's family, friends and the entire IA team during this difficult time. Alan dedicated himself to growing the healthcare staffing industry and he leaves a lasting legacy. Operator, please open the call for questions.

Thank you. [Operator Instructions] Our first question is from Mark Marcon from Baird. Your line is open.

So good afternoon and thanks for taking my questions. Cary that was a nice thing for you to say, obviously. I don't know the family or friends, but obviously, condolences tragic and puts things in perspective. Can you talk a little bit about the VMS wins that you had and the MSP wins that you had, it sounds like you've got five. How big are they? Are they new to using an MSP or VMS? Or were they competitive wins? Any sort of color there would be appreciated.

Yes. A couple of things. One is, I think as you think about just the wins overall, they're reflective of a very intentional strategy, we've had to accelerate our go-to-market particularly, to broaden our positioning across the entirety of the market where we had been MSP-centric for some period of time. And so Mark, a lot of the wins that we are seeing now are manifestations of strategies we put into place over a year ago, just given some of the lead times. For those wins, I'd characterize them as small to medium win. But the names underneath them are - have carry even more weight in a couple of cases and what their, spend under management would indicate, and they were competitive wins. A broader comment that I'll say about what we're seeing, we've seen pipeline - healthy pipeline growth in our sales pipeline from Q4 to Q1. We had been seeing for, I'd say, probably two years coming out of the pandemic, a bias in the pipeline towards vendor neutral. We are just starting to see some swing back, so we're still seeing strong interest in vendor neutral, but we're seeing some swing back in growth in our pipeline in MSP.

That's great. Do you have a size in terms - I mean you said they were small to medium, but when we consolidate them all, like what sort of revenue contribution could they ultimately end up generating at once the...?

If you look at year-to-date, we're in a net client win position. And so think of it as that would help us from a net revenue standpoint as we go later into the year.

Okay. Great. And then can you talk a little bit more about language services and some of the dynamics there. We haven't - historically has been a growing space with really healthy margins. And just wondering about like what you're seeing from a competitive perspective, and how you would expect that to unfold over the quarter and the year ahead?

Yes. So in Language Services overall, we continue to see healthy growth, you will see that in the second quarter, and we expect that to continue as we go through the year. From a competitive standpoint, we have seen particularly over the past 12 plus months some consolidation in the space. And so you have seen that consolidation, particularly among kind of two or three players, happen over 2024 and a bit in 2023. That's putting a bit of pressure on margins. We still see this business as a high-growth, high-margin business and it is very attractive. We are very well positioned with our solution set of video and audio, and so we can offer both a high-quality solution, but given the efficiency of how we deliver our services, it also is a cost-effective solution for clients. So we think we are very well positioned even in a competitive environment.

So would you expect the margins, the gross margins on that part of the business to basically stabilize at these levels? Or how are you thinking about that?

Yes. Mark, this is Brian. I think that's a fair characterization. We've seen a little bit of a decline as we called out. But we also are working internally on always improving the quality of the service, but also how we think about utilization of interpreters, in the mix between permanent and use of contracts, onshore, offshore as well. So we're already making some adjustments that we'll bring down some of our costs. Within no way impacting the quality of our service, which we know is a differentiator. So at this point, we feel like we've got some good actions that, are going to help stabilize even if there's a little more pressure on the price side with some of the competitors. So we're feeling good that this is a good stable point.

Mark, one thing I'll note, just picking up on one of Brian's comments is, it is a differentiator both the kind of our video capabilities, but also our onshore/offshore, so for some clients having the ability to have onshore interpreters, is very important to them, not every competitor offers that option. So that is also a differentiation that, is important to a number of clients and/or prospects that we talk to.

Great. And can I squeeze one more in? Just on travel nurse bill rates. It sounds like they were only down a little bit year-over-year. Do you feel like that's pacing out? I know that there's still some orders out there that aren't competitive. But do you feel like we're starting to see some real basing and a point where we can start building again?

Yes. If you look at the bill rates, we've really seen stabilization from the back half of 2024. So even though we're down 6% year-over-year, it was - you saw stabilization that we talked about in the past quarter as well. Currently, we are at a premium spread of contingent cost to permanent labor of about 11%. Pre pandemic, you would have seen that range more in the mid- to high teens. And so I think as we have talked about over the past couple of quarters, as we've seen some of the stabilization in bill rates, you're continuing to see signs that you have seen some stabilization, unfilled orders are relatively where they were last quarter, maybe a slight uptick. So I think from here on in, really, if there's an immediacy of the need of some of these clinicians you would expect for some of those bill rates, to go up to ensure that they are able to fill that need.

That's great. Thank you very much.

Thanks, Mark.

Thank you. Our next question is from Trevor Romeo with William Blair. Your line is open.

Hi, good afternoon, everyone. Thanks so much for taking the questions. I want to thank you also for providing the slide deck this quarter. That's extremely helpful for us. So I appreciate that. Maybe I'll just pick up on the unbillable order topic. I had a question on that. I mean it definitely appears that order volumes are picking up, across the industry still. I think Cary, you talked about continuing to see orders priced at levels no one's filling, but the margins - gross margins seem a bit more stable this quarter. So two questions on that. One is, are you starting to see competitors taking less of those low-margin orders? And then two, what do you think it will take for clients to move those bill rates higher so that they can be filled?

Yes. So on the first one, I think the unfilled orders is probably reflective of rationality of competitors of not filling orders that don't make economic sense. What we have seen in terms of those unfilled orders getting filled, is it typically is a client going back, and there's a more immediate need of getting that filled and increasing the bill rate to a price that will be reflective of current market conditions, whether that's geographic, or by specialty. And so a part of the challenge that you've had, particularly over the past three or four quarters, is that while you got in 2024, we really started to see the bill rates stabilize. But the underlying labor market, you're still seeing increases in wages. And so, there is a market matching condition that you have to have around the bill rate. To reflect where clinicians are willing to go to take the assignment. And so it's pretty client specific. And as we see more of those needs become more immediate, we would expect some of those bill rates to change.

Yes. In terms of competitive behavior, it seems it's been pretty much the same, right? We're seeing that on field percentage that may be the same or maybe ticking up a bit, which is I think an indication that clients with low rates have kind of tested the bottom and maybe gone too far. And so it's competitors may be filling some orders, but they're not filling these ones that have rates that just don't make economic sense, and that really hasn't changed. I think as we go through this year, if there's a greater need or competitors just realize is it's not going to change, you'll probably see some of them move away from the industry, which should be healthy, longer term. But ideally, clients, if they have pushed it for a while and realized that, that rate is not going to actually attract clinicians in that they'll start to move. And again, it's on a client by client basis, we're definitely seeing that happen, you see it more broadly across the industry.

And Trevor, one other add I would have to Brian's comments, is when you look at some of the things that have improved for the healthcare system, you've seen a return to pre-pandemic retention rates. You saw a reestablishment of their permanent base through accelerated hiring, and so those two things were significant improvements in terms of the stability of their workforce. You now have from a completion strategy, very cost-effective contingent labor cost, and so I do think as you look forward how systems think about the completion of that strategy, it probably will look different than it maybe did 18 months ago when that premium spread was at much higher levels.

Got it. That makes a lot of sense. Thank you both. And then I guess for my follow-up, I wanted to ask on the labor disruption piece. I mean it seems like it's coming ahead of your expectations the last couple of quarters. Cary, you talked about the pipeline. I think some of the recent capabilities have improved in that area. So I guess would you say that the underlying amount of labor disruption is growing? Or is it more about that internal kind of focus and execution and either way, is this an area where you could see kind of a more consistent revenue cadence going forward?

It's more the internal focus and how we operate. So as we went back and looked at the total CBAs in the market last year versus this year, last year was higher. Our pipeline and the clients and the events we're supporting are higher because we've been focused on it. And I'd say it's been on really two very important fronts. One is, it is very clear to us that for clients who have this need, it is a very important need. And our focus is on how we support our clients. The second part really speaks to some of the commentary that I had in the beginning, which is, we now have technology, we have more automation in our business. We have an ability to support important parts of our process 24/7, around the clock globally. And so there are a number of things that we have worked on over the past 12 to 18 months. That have positioned us to be able to support our clients very effectively here while also not affecting the high service quality in our core businesses. And so, we wanted to have confidence that we could do that and make sure that we were not affecting the quality of service that we had in our core. From a modeling standpoint, it's a great question. We still model $5 million of revenue a quarter. It's just not as predictable. But we do have a stronger pipeline. We have more upside than we have had, especially more recently in some of these events.

But it is - it can still be lumpy, because even when there's a an expiring organic agreement, that doesn't necessarily mean that the next day, they go on strike. And so there may be an agreement in place. We're planning for it, but the timing is somewhat unknown and the duration. So we do believe that there will be - we will continue to have the service and there will be strikes that will happen. But in terms of the magnitude and the exact timing, it's still very difficult to predict. The good thing is, as Cary pointed out, we have a team that can support that really well. We now have industry-leading technology behind it. So we feel like we're really well positioned to be able to win those opportunities that come up and provide really critical service, but it is still hard to predict the exact timing and magnitude.

Yes. And if I could maybe just sneak in one quick follow-up on that, Brian, on the incremental margins on that business, can you just maybe remind us what you typically see there relative to your other businesses in that segment?

Yes. It's a fair question. And again, there's lots of variables in that because, again, there's - sometimes if there's work leading up to an event and it doesn't happen, you might get more fees on kind of preparing and that could be a higher margin. But if you - we found over the last couple of years for events that occur. We are - as we've mentioned in the last couple of quarters, where we've had revenue. The gross margins are not materially different than the segment margin. We obviously get more flow through though, the G&A side of it, we definitely have incremental cost. That team is already in place, but travel costs and other logistics support that occurs. So we get a nice flow-through on the EBITDA margin, but the gross margin impact for nurse, and allied is pretty consistent with what you're seeing in our core business.

All right, thank you very much. I appreciate it.

Thank you. Our next question is from A.J. Rice with UBS. Your line is open.

Hi everybody. Maybe a couple here, some of which clarification on previous comments. Just to make sure I understand nurse and allied bill, especially the nursing, the bill rates are stabilizing. You've said that in the last two quarters, but you've also had an uptick in labor disruption. Revenues is on an apples-to-apples basis, putting the labor disruption aside, are you seeing stabilization? Or is that having any influence on sort of helping stabilize the rates?

Yes, thanks for the question. So just to be clear, the labor disruption revenue, those rates are not included in the bill rates that you see us talk about here, and that stability there. So we're really talking about the bill rates for our kind of core travel nurse and travel allied businesses. And that's where we've seen stability for the last several quarters, so the rates on labor disruptions vary quite a bit. They can be higher just, because you're trying to pull in for short duration, but that's not influencing the metrics we're talking about here.

Okay. That's helpful. And then going back to the language services, I understand the comments about the competitive landscape, but you also mentioned in the prepared remarks, a little bit of weakening in demand for Spanish translation services that may be potentially impacted by some of the dynamics out of Washington, begs the question about how much of an impact is that? How big is Spanish translation services in your business? And I guess, if I think about it from what's going on with immigration at all, do you have a lot of that in the emergency room? Or is that more people that are actually admitted to the hospital, et cetera?

We haven't - the language is the number one language for interpretation, and that's not a surprise. What we have seen so far is a modest downturn in Spanish, as a percentage of our total language mix. And so, it's something that we're monitoring as we have typically seen that as very strong growth. It's not something that is - would at this point that we would see impacting. We're actually seeing growth into second quarter, and we would expect that to continue throughout the year. But it's something that we're monitoring. We haven't seen any slowdown in interest or demand from clients. And so, the only place where we have seen any type of impact is a modest downtick in the percentage of Spanish as total minutes offered.

Okay. And then just one last one. I think in the prepared remarks, you mentioned that you had a little pressure in bill pay spread and locum tenens. I know you can have volatility based on the specialists that are in demand at any given time. But I don't think I've heard you say that there was some pressure on the bill pay spread before. What - maybe I'm wrong on that, but what are you seeing there?

Yes. I mean, I think we've probably called it out at times. I mean, there's competition there. And so there's been some pressure on just the spreads overall as we're really trying to drive days bill. And then there has been a component of mix with like our CRNA business, which has been a nice strong growth in days, but it does carry a lower margin impacting the spreads overall for that business. I think we've - and so you see more of an impact on a year-over-year basis. It's much smaller sequentially. And as we look into the second quarter and the remainder of the year, feel like we're in a good place and spreads are starting to stabilize. I think the other important point, I think we mentioned in the last call is that we're seeing good momentum in some of our other specialties now. A lot of - we built up the teams there and some of the internal medicine, psych, surgery, there's other areas that have a better rate and margin profile. The team is very confident that we're going to be able to grow those specialties, which should have a positive influence on our margins longer term.

Okay, thanks a lot.

Thank you. Our next question comes from Brian Tanquilut from Jefferies. Your line is open.

Hi, this is Meghan Holtz on for Jack Slevin, and thank you for taking the question. So just a little bit deeper and beyond the Spanish commentary. Are you guys seeing any apprehension from clients in taking on full-time hires given the background right now on the macro side and the policy uncertainty? Or is it soon to tell?

Yes. I think generally, it's too early to tell. Clients are monitoring the fluid environment around healthcare policy and doing scenario planning. What we have seen and what a lot of the commentary, particularly over the past two weeks from some of the healthcare systems is that they are still seeing a healthy increase in patient demand. And so for us, we had a strong start to the year. We are very focused on how we continue to increase our demand, and fill more of the demand that's out there in the market. The only thing that we have seen from a behavioral standpoint over the past couple of weeks, is we've seen some slowdown in client decision-making. We've seen this off and on over the past two years. And so that is not something that is new to us. And we do think that, particularly with my earlier comments about, where you see some of the premium spread to permanent positions, right now, in this environment, contingent is actually a very attractive alternative. If there's not - while they wait and look at, where some of these policies land.

Okay. And then just a follow-up. Can you guys walk through any updated thoughts on the progression of the international business throughout the balance of the year?

Yes. As we've talked about in the last call, I'd say there's no major changes there. We did expect to see, and we have seen a decline sequentially from Q4 to Q1, call it a $3 million to $4 million range. We'll see a similar amount in the second quarter. And that's really just a function of with retrogression that we've got more nurses coming off their contracts than we're able to place. But that is stabilizing. We still expect until we get to the third quarter. So Q3 and 4 should look a lot like the second quarter. So no longer a headwind after the second quarter from everything we're seeing right now. And we still expect to see that start to turn positive in 2026. As you continue to see those - the visa dates move forward. That's really - other than that, clients want to bring in more international nurses. It's just a function of getting that visa date move forward, so that we can pull more that are in the pipeline into the U.S. and into these assignments.

Yes. What we've seen just to add on to Brian's comment about support is, the need for international clinicians, is supported both in a bipartisan kind of environment, and it's also pretty universally supported by health systems. So it fills a very important need for a number of systems. I'd say particularly those that are nonurban settings that have a harder time being able, to retain and attract talent.

Got it. Thank you for the color.

Thank you. Our next question comes from Jeffrey Silber with BMO Capital Markets. Your line is open.

This is [Ryan] on for Jeff. Just wanted to refresh on the capital allocation priorities at this point in time, is taking leverage ratio down first and foremost. And then just any thoughts on repurchases or M&A? Thanks.

Sure. It's Brian. As I mentioned in our prepared remarks, our -- definitely our priority right now is to continue to use free cash flow to pay down debt. And so that is not going to change to this year. From a capital deployment on CapEx, we've said that our -- we'll expect to spend somewhere between $40 million and $50 million this year. That is a little - a little more than half of what we spent in 2024. So we did adjust our capital expenditures so that we could deploy more towards debt reduction. But that's - I think it's still creating a different - quite a differentiation for AMN and that we're still investing in innovation, in AI, things that are going to continue to improve our service delivery speed and fulfillment. And so I think that's where maybe some of our other competitors that are having to pull back even more on the CapEx, we're excited about what we're bringing forward here. You hear us talk about it in the investments, we're making across the business. And so we're - we think those are really important to our long-term strategy, but it's a good balance between deploying for those important investments, but also paying down our debt and keeping that leverage within our covenants.

Got it. Thank you. And then just a follow-up on one of the prior questions, was curious how things trended throughout the quarter and exited the quarter. I was wondering if you noticed any incremental hesitancy from clients either post DOGE, or tariff announcements or anything to call out there?

No. We continue to see strong demand. So if you kind of look at our businesses, we continue to see strong demand in allied, locum, strike, school bookings, language services. In nurse, we are still year-to-date through April versus the year-over-year comparison were up mid-teens. In that, we did see some - a bit of pullback in April, but even with that, we're still up 15% year-over-year. So we continue to see healthy demand in the businesses. The one thing that, as I mentioned earlier, that we have seen is some slowdown in decision-making. So once a candidate has presented the decision-making around that or around an extension.

Thank you for your question. Our next question comes from Joanna Gajuk from Bank of America Securities. Your line is open.

Hi, thanks so much for taking the question. Maybe a couple of questions on your guidance. I don't think I've heard some of the metrics that you normally discuss. So would you assume for the Nurse, Allied volumes in Q2 and also for the build rates in Q2? And the last piece is gross margin for nurse allied in Q2, I guess, you did 22.7% I think in Q1, so that was better than what you had assumed? So kind of maybe if you can give us some of these assumptions, that will be helpful? Thank you.

Yes. I don't - yes, I don't think we're going to give that specific level of detail. We did mention in the prepared remarks that there is -- we expect to see kind of normal seasonality in nursing, which if you go back it's not uncommon to see our volume come down, from Q1 to Q2 with some of those winter assignments end. So we're expecting to see that sequentially, sit kind of a normalized pattern low single digits. Allied, again underneath Allied, again, good demand in our core Allied business schools. You typically do see a decline from first and second quarter gains you're moving into the summer months. So I'd say in that regard, it's pretty similar on the rate side, again, the stable rate bill rate going from Q1 to Q2. The only influence, again, some of those winter assignment orders might have had a little bit higher rate attached to them. But underneath that, we've seen stability in rates as well.

And I guess on the gross margin overall in Q1, you mentioned that mentioned, but we can see that it was better than your guidance. So what actually drove the outperformance there? And I guess then for your Q2 guidance on the overall gross margin, you could assume kind of stable maybe actually up at the midpoint, a little bit 10 basis points or so. So can you walk us through the outperformance in Q1? And then I guess why are you thinking the gross margins could actually be up sequentially? Thank you.

Sure. I mean there weren't any major drivers of that outperformance in Q1. We did have a - we had a workers' comp actuarial, a favorable adjustment of about $1.5 million that was - that has about 20 basis points. We did have a little bit better performance in our VMS revenue, which is high-margin search as well. So it was kind of a sum of several small things that ended up driving outperformance in the gross margin in the first quarter. The guide we've given for Q2, would imply down a little bit, part of that being driven by that onetime workers' comp adjustment in the first quarter, not happening again in the second quarter. And then the rest of it is really predominantly just mix. We're seeing pretty stable margins. Nothing I'd call out is highly notable from Q1 to Q2.

Thank you.

Thank you. Our next question is from Tobey Sommer from Truist. Your line is open.

Good afternoon. This is Tyler Barishaw for Tobey. You mentioned in the prepared remarks some changes to your gross margins with some process changes with technology. Can you just be a little more detail on what some of those are?

Yes. So part of what we have been doing is, we just rolled out after development in the back half of the year, a gross margin tool. And so part of what we have been focused on in our technology investments is how do, we create both automation but efficiency. And so that has been very well received. It will create about a 4% on average productivity improvement, for our recruiters. And so those tools are really helpful in us both attracting, but also retaining the top recruiting talent. The other pieces that you've seen us focus on in our technology that helps, our ability to generate revenue are AI matching. So we put in the fourth quarter in our Locums business. We put AI matching capabilities with candidates that help recruiters with their speed. If we look year-over-year in our locum sales, it has gone up considerably and some of that tech enablement is a part of it.

And there's continued - I mean it's daily, weekly, we're rolling out new enhancements in our - the tools that we're providing to our recruiters, some of it we can't share necessarily from a competitive point of view, but just know that, that we're getting really good internal reaction to some of the investments we're making, continuing to build out AMN Passport for the clinicians as well to make it easier for them to onboard, search for jobs, credentials. So that - and really create a more cohesive integrated platform between ShiftWise Flex, our internal append tracking system, Passport. So everything is very well connected and things flow more seamlessly, which, in all cases, improve speed and experience both for clients, clinicians and our internal teams.

Got it. And then can you just discuss some competition in the marketplace. Has competition eased at all in the last couple of months, especially with a peer being acquired potentially?

Yes. The competition is still very intense. The acquisition - the IO Cross Country acquisition is not complete yet. So they are still competitors. And we expect that competitive environment to stay intense. There is over - there is more competition for the demand that's out there. You start to see a rationalization and consolidation already over the past year. We think that more has to happen, over the coming years. And so we would expect both for it to continue to be a competitive environment, and for there to be continued rationalization of the capacity that's in the market. Really kind of furthering some of Brian's earlier comments, if we look at our capabilities, which includes our platforms, our broad solutions our extraordinary team. We think that we are well positioned in that very competitive environment, and we are seeing that increasingly with our client wins, with our improved fill rate, with our ability to win against the entirety of the market from MSPs vendor-neutral direct.

Thank you.

Thank you. I'm showing no other questions at this time. So I would now like to turn it back to Cary Grace, for closing remarks.

Thank you all for your interest in AMN, and for tuning into our conference call. And I want to do a shout out both to our AMN team members, who got us off to a strong start to 2025, as well as to say a special note of gratitude to every nurse out there, as we celebrate you through the entirety of this month. Thank you.

This does conclude the program. You may now disconnect. Have a good day.